We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+0.48%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$103M
Cap. Flow
+$76.4M
Cap. Flow %
7.03%
Top 10 Hldgs %
55.27%
Holding
75
New
18
Increased
23
Reduced
22
Closed
7

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$24.3M
2
UNH icon
UnitedHealth
UNH
+$23.2M
3
RVTY icon
Revvity
RVTY
+$19.9M
4
AVTR icon
Avantor
AVTR
+$19.2M
5
ILMN icon
Illumina
ILMN
+$16.1M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.9M
2
HQY icon
HealthEquity
HQY
+$18.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$18.5M
4
NTRA icon
Natera
NTRA
+$15.2M
5
GSK icon
GSK
GSK
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.21%
2 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGEN icon
51
Repligen
RGEN
$7.44B
$2.32M 0.21%
18,620
+168
+0.9% +$21.4K
GOSS icon
52
Gossamer Bio
GOSS
$66.5M
$2.09M 0.19%
1,695,762
-2,201,079
-56% -$2.4M
GPCR icon
53
Structure Therapeutics
GPCR
$3.49B
$2.06M 0.19%
+99,338
New +$2.18M
RLAY icon
54
Relay Therapeutics
RLAY
$4.02B
$1.85M 0.17%
+533,409
New +$1.59M
STRO icon
55
Sutro Biopharma
STRO
$379M
$1.64M 0.15%
229,226
– –
MRVI icon
56
Maravai LifeSciences
MRVI
$997M
$1.54M 0.14%
640,673
-301,781
-32% -$634K
BCYC
57
Bicycle Therapeutics
BCYC
$270M
$1.47M 0.14%
+211,469
New +$1.68M
AUTL
58
Autolus Therapeutics
AUTL
$386M
$1.39M 0.13%
610,231
+266,284
+77% +$440K
IFRX icon
59
InflaRx
IFRX
$256M
$1.3M 0.12%
1,640,430
-35,548
-2% -$42K
PNTG icon
60
Pennant Group
PNTG
$1.43B
$1.13M 0.1%
+37,980
New +$1.04M
KPTI icon
61
Karyopharm Therapeutics
KPTI
$168M
$1.11M 0.1%
257,154
– –
ITOS
62
DELISTED
iTeos Therapeutics
ITOS
$1.09M 0.1%
109,324
-110,872
-50% -$893K
FTRE icon
63
Fortrea Holdings
FTRE
$1.85B
$1.08M 0.1%
219,384
-73,891
-25% -$397K
PBYI icon
64
Puma Biotechnology
PBYI
$406M
$826K 0.08%
240,688
-35,100
-13% -$112K
ARCT icon
65
Arcturus Therapeutics
ARCT
$157M
$629K 0.06%
+48,364
New +$572K
EHTH icon
66
eHealth
EHTH
$42.5M
$558K 0.05%
128,322
+39,102
+44% +$196K
MODV
67
DELISTED
ModivCare
MODV
$312K 0.03%
+100,000
New +$184K
ACIU icon
68
AC Immune
ACIU
$227M
$205K 0.02%
100,752
– –
ALGN icon
69
Align Technology
ALGN
$12B
– –
-49,277
Closed -$7.83M
NBIX icon
70
Neurocrine Biosciences
NBIX
$17.7B
– –
-167,243
Closed -$18.5M
NVAX icon
71
Novavax
NVAX
$1.23B
– –
-365,523
Closed -$2.34M
QQQ icon
72
Invesco QQQ Trust
QQQ
$455B
– –
-24,003
Closed -$11.9M
SPY icon
73
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
– –
-76,900
Closed -$43M
TFX icon
74
Teleflex
TFX
$5.85B
– –
-56,630
Closed -$7.83M
XOMA
75
DELISTED
Xoma
XOMA
– –
-45,017
Closed -$897K
1 2
3

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Eversept Partners held 75 positions worth $1.09B, up 10% from $985M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Eversept Partners deployed $76.4M of net new capital in Q2 2025, opening 18 new positions and adding to 23 existing holdings. Its largest new stake was UnitedHealth: 60,736 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was HCA Healthcare, an estimated $18.9M trimmed.

  • Eversept Partners's largest Q2 2025 buy was UnitedHealth: 60,736 shares worth $18.9M.
  • Eversept Partners added most to Vaxcyte in Q2 2025, an estimated $24.3M increase.
  • Eversept Partners's biggest Q2 2025 reduction was HCA Healthcare, cutting an estimated $18.9M.
  • Eversept Partners fully exited Neurocrine Biosciences in Q2 2025, selling an estimated $18.5M.
  • Eversept Partners's ten largest holdings make up 55% of its $1.09B portfolio in Q2 2025.
  • Eversept Partners opened 18 new positions and closed 7 in Q2 2025.
  • Eversept Partners's portfolio value rose 10% quarter-over-quarter to $1.09B.

Based on Eversept Partners's 13F filing for Q2 2025, filed 14 Aug 2025.